GGHC
JUNO

Gilder Gagnon Howe & Co’s Juno Therapeutics, Inc. JUNO Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-2,893
Closed -$154K – 294
2015
Q2 		$154K Sell
2,893
-71,906
-96% -$3.82M ﹤0.01% 250
2015
Q1 		$4.54M Buy
74,799
+25,242
+51% +$1.22M 0.06% 145
2014
Q4 		$2.59M Buy
+49,557
New +$2.22M 0.04% 174

Other funds holding JUNO

CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GAMA
Graticule Asia Macro Advisors New York $649M AUM

Gilder Gagnon Howe & Co's JUNO Position: Q3 2015 in Review

Gilder Gagnon Howe & Co sold out of Juno Therapeutics, Inc. (JUNO) in Q3 2015, closing a stake of 2,893 shares — an estimated $154K sold.

Gilder Gagnon Howe & Co first reported a position in JUNO in Q4 2014 and held it in 3 quarters. The position peaked at $4.54M in Q1 2015. 132 funds tracked by Wall St. Rank hold JUNO as of Q3 2015.

  • Gilder Gagnon Howe & Co reported no remaining Juno Therapeutics, Inc. position as of Q3 2015 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 2,893 Juno Therapeutics, Inc. shares in Q3 2015, an estimated $154K.
  • Gilder Gagnon Howe & Co first reported a position in Juno Therapeutics, Inc. in Q4 2014 and held it in 3 quarters.
  • Gilder Gagnon Howe & Co's Juno Therapeutics, Inc. position peaked at $4.54M in Q1 2015.
  • 132 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q3 2015.

Based on Gilder Gagnon Howe & Co's 13F filing for Q3 2015, filed 9 Nov 2015.